- Home
- TBLD vs ORIC Comparison
TBLD vs ORIC Comparison
Compare TBLD & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLD
- ORIC
- Stock Information
- Founded
- TBLD 2021
- ORIC 2014
- Country
- TBLD United States
- ORIC United States
- Employees
- TBLD N/A
- ORIC N/A
- Industry
- TBLD Investment Managers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- TBLD Finance
- ORIC Health Care
- Exchange
- TBLD Nasdaq
- ORIC Nasdaq
- Market Cap
- TBLD 543.1M
- ORIC 545.5M
- IPO Year
- TBLD N/A
- ORIC 2020
- Fundamental
- Price
- TBLD $17.84
- ORIC $5.53
- Analyst Decision
- TBLD
- ORIC Strong Buy
- Analyst Count
- TBLD 0
- ORIC 9
- Target Price
- TBLD N/A
- ORIC $18.43
- AVG Volume (30 Days)
- TBLD 65.2K
- ORIC 734.5K
- Earning Date
- TBLD 01-01-0001
- ORIC 05-05-2025
- Dividend Yield
- TBLD 7.01%
- ORIC N/A
- EPS Growth
- TBLD N/A
- ORIC N/A
- EPS
- TBLD N/A
- ORIC N/A
- Revenue
- TBLD N/A
- ORIC N/A
- Revenue This Year
- TBLD N/A
- ORIC N/A
- Revenue Next Year
- TBLD N/A
- ORIC N/A
- P/E Ratio
- TBLD N/A
- ORIC N/A
- Revenue Growth
- TBLD N/A
- ORIC N/A
- 52 Week Low
- TBLD $15.19
- ORIC $5.26
- 52 Week High
- TBLD $18.03
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- TBLD 60.10
- ORIC 30.08
- Support Level
- TBLD $17.66
- ORIC $5.78
- Resistance Level
- TBLD $17.88
- ORIC $8.11
- Average True Range (ATR)
- TBLD 0.20
- ORIC 0.52
- MACD
- TBLD -0.01
- ORIC -0.14
- Stochastic Oscillator
- TBLD 67.07
- ORIC 9.57
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.